Core Insights - On October 23, Yuheng Pharmaceutical experienced a decline of 1.53% with a trading volume of 137 million yuan, indicating a negative market sentiment towards the company [1] - The company reported a financing net buy of -3.40 million yuan on the same day, suggesting a higher level of selling pressure compared to buying [1] - As of October 23, the total margin balance for Yuheng Pharmaceutical stood at 380 million yuan, which is 5.37% of its circulating market value, indicating a relatively high leverage position [1] Financing and Margin Data - On October 23, the financing buy amount was 14.50 million yuan, while the financing repayment was 17.90 million yuan, leading to a net financing outflow [1] - The current financing balance of 380 million yuan exceeds the 70th percentile level over the past year, indicating a significant level of borrowing [1] - In terms of securities lending, there were no shares sold on October 23, with a total of 0 shares in the lending balance, which is at the 80th percentile level over the past year [1] Company Financial Performance - As of September 19, the number of shareholders for Yuheng Pharmaceutical was 105,700, a decrease of 1.03% from the previous period, while the average circulating shares per person increased by 1.04% to 19,831 shares [2] - For the first half of 2025, the company reported a revenue of 1.10 billion yuan, a year-on-year decrease of 9.97%, while the net profit attributable to shareholders was 134 million yuan, reflecting a year-on-year increase of 7.56% [2] Dividend and Shareholding Information - Since its A-share listing, Yuheng Pharmaceutical has distributed a total of 692 million yuan in dividends, with no dividends paid in the last three years [3] - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, holding 31.23 million shares as a new shareholder [3]

Core Viewpoint - The company, Harbin Yuheng Pharmaceutical Co., Ltd., has achieved the conditions for the first lock-up period release of its 2024 restricted stock incentive plan, allowing 40 eligible participants to unlock a total of 3,872,000 shares, which represents approximately 0.1724% of the company's total share capital [2][10]. Summary by Sections Incentive Plan Details - The first lock-up period for the reserved grant of the 2024 restricted stock incentive plan has been fulfilled, with the release date set for October 22, 2025 [3][16]. - The company completed the approval process for the incentive plan, including board and shareholder meetings, from January to March 2024 [4][5]. Stock Grant and Repurchase - The company granted a total of 72,391,000 shares of restricted stock to 105 participants on March 12, 2024, and has conducted repurchases of shares from departing employees [5][8]. - As of October 10, 2024, the company completed the registration of 10,180,000 shares for reserved grants to 43 participants [8]. Lock-up Release Conditions - The conditions for the release of the restricted stock include meeting specific performance criteria as outlined in the incentive plan [13]. - The first lock-up period for the reserved grant shares ended on October 10, 2025, allowing for the release of shares [13]. Share Structure Changes - The release of the restricted shares will result in changes to the company's share structure, with the total number of shares released being 3,872,000, which is 40% of the total reserved grant shares [16]. - The final changes to the share structure will be confirmed based on the registration data from the China Securities Depository and Clearing Corporation [16].

Core Points - Harbin Yuheng Pharmaceutical Co., Ltd. announced that the first lock-up period for its 2024 restricted stock incentive plan has been lifted, allowing 40 eligible participants to unlock their shares [1] - A total of 3,872,000 shares, representing approximately 0.1724% of the company's total share capital, will be released from restrictions [1] - The unlocked shares will be available for trading starting from October 22, 2025 [1]

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-075 哈尔滨誉衡药业股份有限公司 2、本次解除限售的限制性股票上市流通日为 2025 年 10 月 22 日。 公司于 2025 年 10 月 13 日召开的第七届董事会第五次会议审议通过了《关 于 2024 年限制性股票激励计划预留授予部分第一个限售期解除限售条件成就的 议案》。根据《上市公司股权激励管理办法》、《2024 年限制性股票激励计划 （草案）》（以下简称"《激励计划》"）、《2024 年限制性股票激励计划实施 考核管理办法》（以下简称"《考核管理办法》"）等的规定，公司 2024 年限 制性股票激励计划（以下简称"本激励计划"）预留授予部分第一个限售期解除限 售条件已经成就。现就有关事项公告如下： 一、本激励计划已履行的审批程序 1、2024 年 1 月 15 日，公司第六届董事会第十一次会议、第六届监事会第 九次会议审议通过了《关于<2024 年限制性股票激励计划（草案）>及其摘要的 议案》等相关议案。 2、2024 年 1 月 16 日至 2024 年 1 月 25 日，公司在公司官方网站公示了拟 ...

Core Viewpoint - Yuheng Pharmaceutical announced that the company and its subsidiaries have no external guarantees, overdue external guarantees, or any litigation related to external guarantees, nor any losses due to judgments against guarantees [2] Summary by Categories - **Company Guarantees** - The company confirmed that there are no external guarantees in place [2] - There are no overdue external guarantees reported [2] - The company has no involvement in any litigation related to external guarantees [2] - There are no losses incurred from judgments against guarantees [2]

Group 1 - The core point of the article is that Yuheng Pharmaceutical (SZ 002437) held its seventh fifth board meeting on October 13, 2025, via telecommunication, where it reviewed the proposal to amend the "External Guarantee Management System" [1] - For the first half of 2025, Yuheng Pharmaceutical's revenue composition was as follows: chemical drugs accounted for 90.39%, traditional Chinese medicine for 9.38%, and other businesses for 0.22% [1] - As of the time of reporting, Yuheng Pharmaceutical had a market capitalization of 7.1 billion yuan [1]

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-074 哈尔滨誉衡药业股份有限公司 关于 2024 年限制性股票激励计划预留授予部分 第一个限售期解除限售条件成就的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、哈尔滨誉衡药业股份有限公司（以下简称"公司"）2024 年限制性股票 激励计划预留授予部分第一个限售期解除限售条件已经成就，本次符合解除限售 条件的激励对象共计 40 人，可解除限售的限制性股票数量为 3,872,000 股，约占 公司目前总股本的 0.1724%。 2、本次限制性股票办理完解除限售手续后、上市流通前，公司将披露限制 性股票上市流通的提示性公告，敬请投资者注意。 公司于 2025 年 10 月 13 日召开的第七届董事会第五次会议审议通过了《关 于 2024 年限制性股票激励计划预留授予部分第一个限售期解除限售条件成就的 议案》。根据《上市公司股权激励管理办法》、《2024 年限制性股票激励计划 （草案）》（以下简称"《激励计划》"）、《2024 年限制性股票激励计划 ...

北京植德律师事务所 关于 哈尔滨誉衡药业股份有限公司 法律意见书 植德(证)字[2024]002-8 号 二〇二五年十月 北京植德律师事务所 Merits & Tree Law Offices 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层 邮编: 100007 12th Floor, Raffles City Beijing Office Tower, No.1 Dongzhimen South Street, Dongcheng District, Beijing 100007 P.R.C 电话(Tel):010-56500900 传真(Fax):010-56500999 www.meritsandtree.com 北京植德律师事务所 关于哈尔滨誉衡药业股份有限公司 2024 年限制性股票激励计划之 预留授予部分第一个限售期解除限售事宜的 2024 年限制性股票激励计划之 预留授予部分第一个限售期解除限售事宜的 法律意见书 植德(证)字[2024]002-8 号 致:哈尔滨誉衡药业股份有限公司 根据北京植德律师事务所(以下简称"本所")与哈尔滨誉衡药业股份有限 公司(以下简称"公司")签署的《 ...

哈尔滨誉衡药业股份有限公司 哈尔滨誉衡药业股份有限公司 第二章 对外担保的审查与控制 第 1页 哈尔滨誉衡药业股份有限公司 对外担保管理制度 第一章 总则 第一条 为规范公司的对外担保行为，控制公司资产运营风险，确保公司的 资产安全，维护投资者利益，根据《中华人民共和国公司法》、《中华人民共和 国证券法》、《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自 律监管指引第 1 号——主板上市公司规范运作》、《公司章程》等法律、行政法 规和规范性文件的相关规定，制定本制度。 第二条 本制度所称"对外担保"是指公司以第三人身份以自有资产或信誉 为他人提供的保证、资产抵押、质押以及其他担保事宜，包括公司对控股子公司 担保在内的对外担保总额与公司控股子公司对外担保总额之和。具体种类包括但 不限于借款担保、银行开立信用证和银行承兑汇票担保、开具保函的担保等。 第三条 公司为自身债务提供担保不适用本制度。 第四条 公司控股子公司的对外担保包括控股子公司之间、控股子公司与其 子公司之间的担保，比照本制度规定执行。公司控股子公司应在董事会或股东会 做出决议前报公司核准，控股子公司应在董事会或股东会做出决议后，及时通知 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-073 哈尔滨誉衡药业股份有限公司 关于为全资下属公司申请银行综合授信提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 担保协议将在公司董事会审议通过本次担保事项后签订。 二、被担保人基本情况 ㈠ 广州誉东健康制药有限公司 1、被担保人名称：广州誉东健康制药有限公司（以下简称"誉东制药"） 2、成立时间：2008 年 10 月 15 日 3、住所：广州市经济技术开发区南翔三路 1 号 一、担保情况概述 2025 年 10 月 13 日，哈尔滨誉衡药业股份有限公司（以下简称"公司"） 第七届董事会第五次会议审议通过了《关于为全资下属公司申请银行综合授信提 供担保的议案》。具体内容详见同日披露于《中国证券报》、《证券时报》及巨 潮资讯网 http://www.cninfo.com.cn 的《第七届董事会第五次会议决议公告》。 根据《深圳证券交易所股票上市规则》及《公司章程》等相关规定，本担保 事项不构成关联交易，无需提交股东会审议批准。 4、法定代表人：周康 ...